Study Stopped
The register will no longer be maintained on a prospective basis
SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
SwissNET
SwissNET - a Prospective Registry of Patients With Neuroendocrine Tumours in Switzerland
2 other identifiers
observational
1,245
1 country
55
Brief Summary
Gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) are regarded as a fairly rare disease. They are derived from the neuroendocrine system of the gastrointestinal tract and the pancreas and share common clinical features. So far, there is still uncertainty about the cell biology and mechanistic regulation of these tumours. Therefore targeted treatment is limited and management challenging. Treatment options include surgery, medical and ablative therapy, and more recently peptide-receptor radionuclide therapy. In order to better understand the characteristics of GEP-NETs and to evaluate treatment strategies, the SwissNET registry aims at the collection of data from patients presenting with a GEP-NET in Switzerland. Data will be entered prospectively and anonymized in a specifically designed database after the patient has given informed consent. All hospitals and general practitioners are invited to report on patients with a GEP-NET diagnosis and to participate to the registry. Data will be evaluated within regular time frames, focussing on types of GEP-NETs, treatment modalities and patient outcomes (e.g. mortality, hospitalisation rate), thereby contributing to the better understanding of these tumours.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2008
Longer than P75 for all trials
55 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2008
CompletedFirst Submitted
Initial submission to the registry
December 24, 2009
CompletedFirst Posted
Study publicly available on registry
December 25, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2025
CompletedSeptember 11, 2026
September 1, 2026
17.7 years
December 24, 2009
September 8, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Tumor-related mortality
Every 5 years
Secondary Outcomes (2)
Incidence of GEP-NET in Switzerland
Every 5 years
Effect of specific treatment strategies
Every 5 years
Study Arms (1)
1
Patients with a histologically confirmed diagnosis of a neuroendocrine tumor irrespective of primary tumor location
Eligibility Criteria
Patients will be selected either through the report of a pathological institute or of any medical doctor within Switzerland treating patients with neuroendocrine tumours.
You may qualify if:
- Neuroendocrine tumor irrespective of primary tumor location
- Diagnosis in Switzerland
- Given informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Insel Gruppe AG, University Hospital Bernlead
- Cantonal Hospital of St. Gallencollaborator
- University Hospital, Basel, Switzerlandcollaborator
- University Hospital, Genevacollaborator
- University of Lausanne Hospitalscollaborator
- University Hospital, Zürichcollaborator
- Triemlispital Zurichcollaborator
- Spitalnetz Berncollaborator
- Ente Ospedaliero Cantonale, Bellinzonacollaborator
- Luzerner Kantonsspitalcollaborator
- Kantonsspital Liestalcollaborator
- Spital Limmattal Schlierencollaborator
- Waid City Hospital, Zurichcollaborator
- Spital STS AGcollaborator
- Kantonsspital Graubündencollaborator
Study Sites (55)
Kantonsspital Aarau
Aarau, Switzerland
Spitalnetz Bern Aarberg
Aarberg, Switzerland
Bezirksspital Affoltern
Affoltern am Albis, Switzerland
Kantonsspital Uri, Altdorf
Altdorf, Switzerland
St. Claraspital
Basel, Switzerland
Universitätsspital Basel
Basel, Switzerland
Istituto oncologico della Svizzera italiana
Bellinzona, Switzerland
Div. of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital
Bern, 3010, Switzerland
Spital Tiefenau, Spitalnetz Bern
Bern, Switzerland
Zieglerspital Bern
Bern, Switzerland
Spitalzentrum Biel - Bienne
Biel, Switzerland
Kantonsspital Bruderholz
Bruderholz, Switzerland
Regionsspital Emmental
Burgdorf, Switzerland
Kantonsspital Chur
Chur, Switzerland
Private practise Dr. Mannhart
Churwalden, Switzerland
Hôpital du Jura
Delémont, Switzerland
Spital Dornach
Dornach, Switzerland
Regionalspital Einsiedeln
Einsiedeln, Switzerland
Hôpitaux Universitaires de Genève
Geneva, Switzerland
Spital Grabs
Grabs, Switzerland
See-Spital Horgen
Horgen, Switzerland
Spital Zimmerberg
Horgen, Switzerland
Fmi Spital Interlaken
Interlaken, Switzerland
Spital Lachen
Lachen, Switzerland
Spital Region Oberaargau
Langenthal, Switzerland
Kantonsspital Laufen
Laufen, Switzerland
Centre hospitalier universitaire vaudois, CHUV
Lausanne, Switzerland
Kantonsspital Liestal
Liestal, Switzerland
Hirslandenklinik St. Anna
Lucerne, Switzerland
Kantonsspital Luzern
Lucerne, Switzerland
Kantonsspital Sursee, Luzern
Lucerne, Switzerland
Kreisspital Männedorf
Männedorf, Switzerland
Kantonsspital Münsterlingen
Münsterlingen, Switzerland
Kantonsspital Olten
Olten, Switzerland
Gesundheitszentrum Fricktal
Rheinfelden, Switzerland
Kantonsspital St. Gallen
Sankt Gallen, Switzerland
Kantonsspital Obwalden
Sarnen, Switzerland
Spital Limmattal
Schlieren, Switzerland
Spital Schwyz
Schwyz, Switzerland
Privatpraxis Dr. H.J. Poths
Seuzach Dorf, Switzerland
Centre hospitalier du centre du Valais
Sion, Switzerland
Bürgerspital Solothurn
Solothurn, Switzerland
Kantonsspital Nidwalden
Stans, Switzerland
Thun Spital STS AG
Thun, Switzerland
Spital Uster
Uster, Switzerland
Regionalspital Visp
Visp, Switzerland
Kantonsspital Winterthur
Winterthur, Switzerland
Kantonsspital Wolhusen
Wolhusen, Switzerland
Spital Zollikerberg
Zollikerberg, Switzerland
Zuger Kantonsspital AG
Zug, Switzerland
Pathologie Medica Zürich
Zurich, Switzerland
Stadtspital Triemli
Zurich, Switzerland
Stadtspital Waid
Zurich, Switzerland
Universitätsspital Zürich
Zurich, Switzerland
STS AG Spital Zweisimmen
Zweisimmen, Switzerland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Aurel Perren, MD
Institute of Pathology, University of Bern, Bern
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 24, 2009
First Posted
December 25, 2009
Study Start
January 1, 2008
Primary Completion
August 31, 2025
Study Completion
August 31, 2025
Last Updated
September 11, 2026
Record last verified: 2026-09